{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:41:59Z","timestamp":1790775719464,"version":"4.1.0"},"reference-count":66,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T00:00:00Z","timestamp":1701648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Vitiligo, the most prevalent skin depigmenting disease, is characterized by the selective loss of melanocytes, impacting patients\u2019 quality of life significantly. This autoimmune disorder progresses through a complex interplay of genetic and non-genetic factors, posing challenges in comprehending its pathogenesis and devising effective treatment strategies for achieving remission. Existing conventional therapeutic approaches, such as topical and oral corticosteroids, calcineurin inhibitors, and phototherapy, lack specificity, offer modest efficacy, and may entail potential adverse effects. Consequently, there is a pressing need for a more nuanced understanding of vitiligo\u2019s pathogenesis to pave the way for targeted therapeutic innovations. This review aims to provide a comprehensive overview of recent developments and findings concerning Januse Kinase (JAK) inhibitors and biologics tested in vitiligo patients. JAK inhibitors have exhibited promising results, showcasing both efficacy and tolerability. In contrast, the outcomes of biologics treatment have been more varied. However, to establish a clearer understanding of which specific pathways to target for a more effective approach to vitiligo, additional in vitro studies and extensive clinical research involving a larger population are imperative.<\/jats:p>","DOI":"10.3390\/jcm12237486","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T05:28:21Z","timestamp":1701667701000},"page":"7486","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Updates on Potential Therapeutic Approaches for Vitiligo: Janus Kinase Inhibitors and Biologics"],"prefix":"10.3390","volume":"12","author":[{"given":"Valentina","family":"Pala","sequence":"first","affiliation":[{"name":"Dermatology Clinic, Medical Sciences Department, University of Turin, 10121 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0098-1406","authenticated-orcid":false,"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Medical Sciences Department, University of Turin, 10121 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Medical Sciences Department, University of Turin, 10121 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7386-3219","authenticated-orcid":false,"given":"Luca","family":"Mastorino","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Medical Sciences Department, University of Turin, 10121 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/1346-8138.15743","article-title":"Vitiligo: A focus on pathogenesis and its therapeutic implications","volume":"48","author":"Bergqvist","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1755-148X.2012.00997.x","article-title":"Revised classification\/nomenclature of vitiligo and related issues: The Vitiligo Global Issues Consensus Conference","volume":"25","author":"Ezzedine","year":"2012","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1590\/abd1806-4841.20142717","article-title":"Vitiligo\u2014Part 2\u2014classification, histopathology and treatment","volume":"89","author":"Faria","year":"2014","journal-title":"An. Bras. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/ijd.16090","article-title":"Clinicodemographic features of mixed vitiligo: A case\u2013control study","volume":"61","author":"Kumar","year":"2022","journal-title":"Int. J. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Iwanowski, T., Ko\u0142kowski, K., Nowicki, R.J., and Soko\u0142owska-Wojdy\u0142o, M. (2023). Etiopathogenesis and Emerging Methods for Treatment of Vitiligo. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119749"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev-immunol-100919-023531","article-title":"Vitiligo: Mechanisms of Pathogenesis and Treatment","volume":"38","author":"Frisoli","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/jocd.14770","article-title":"Biologic and targeted therapeutics in vitiligo","volume":"22","author":"Karagaiah","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"986918","DOI":"10.3389\/fimmu.2022.986918","article-title":"Advances in vitiligo: Update on therapeutic targets","volume":"13","author":"Feng","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s40257-017-0298-5","article-title":"Vitiligo: An Update on Pathophysiology and Treatment Options","volume":"18","author":"Speeckaert","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","article-title":"Tofacitinib Citrate for the Treatment of Vitiligo","volume":"151","author":"Craiglow","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e15821","DOI":"10.1111\/dth.15821","article-title":"Effectiveness and safety of tofacitinib combined with narrowband ultraviolet B phototherapy for patients with refractory vitiligo in real-world clinical practice","volume":"35","author":"Song","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3889\/oamjms.2018.042","article-title":"Micro\u2014Focused Phototherapy Associated To Janus Kinase Inhibitor: A Promising Valid Therapeutic Option for Patients with Localized Vitiligo","volume":"6","author":"Gianfaldoni","year":"2018","journal-title":"Open Access Maced. J. Med. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5152\/eurjrheum.2020.20007","article-title":"Tofacitinib-induced remission simultaneously in arthritis and vitiligo","volume":"8","author":"Scheinberg","year":"2021","journal-title":"Eur. J. Rheumatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamadermatol.2017.5778","article-title":"Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy","volume":"154","author":"Kim","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","article-title":"Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure","volume":"77","author":"Liu","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/09546634.2017.1339013","article-title":"Importance of light in the treatment of vitiligo with JAK-inhibitors","volume":"29","author":"Joshipura","year":"2018","journal-title":"J. Dermatol. Treat."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/phpp.12661","article-title":"Evaluation of low-dose tofacitinib combining narrowband UVB therapy for treating vitiligo patients who had failed previous therapy: A pilot study","volume":"37","author":"Fang","year":"2021","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/ced.15070","article-title":"Low-dose tofacitinib with 308-nm excimer therapy successfully induced repigmentation in patients with refractory vitiligo","volume":"47","author":"Fang","year":"2021","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.abd.2019.08.032","article-title":"Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation","volume":"95","author":"Komnitski","year":"2020","journal-title":"An. Bras. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/ccr3.2759","article-title":"Effective use of oral tofacitinib and phototherapy in a patient with concomitant alopecia areata, vitiligo, and plaque and inverse psoriasis","volume":"8","author":"Tajalli","year":"2020","journal-title":"Clin. Case Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/ced.13290","article-title":"Oral tofacitinib: A promising treatment in atopic dermatitis, alopecia areata and vitiligo","volume":"42","author":"Vu","year":"2017","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000513938","article-title":"Topical Tofacitinib: A Janus Kinase Inhibitor for the Treatment of Vitiligo in an Adolescent Patient","volume":"13","author":"Ferreira","year":"2021","journal-title":"Case Rep. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/bjd.18606","article-title":"Open-label pilot study of tofacitinib 2% for the treatment of refractory vitiligo","volume":"182","author":"Mobasher","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/pde.14159","article-title":"Tofacitinib cream plus narrowband ultraviolet B phototherapy for segmental vitiligo in a child","volume":"37","author":"Olamiju","year":"2020","journal-title":"Pediatr. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jaad.2019.04.032","article-title":"A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo","volume":"81","author":"McKesey","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of vitiligo: A randomised, controlled, phase 2 trial","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib","volume":"76","author":"Rothstein","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.jaad.2018.02.023","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B","volume":"78","author":"Joshipura","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Camacho, M.B., Han, M.M., Wang, J.N.B., Dermarkarian, C.R., and Tao, J.P.M. (2023). Eyelid Vitiligo Treatment with Topical Ruxolitinib. Ophthalmic Plast. Reconstr. Surg.","DOI":"10.1097\/IOP.0000000000002461"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","article-title":"Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)","volume":"74","author":"Harris","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/ajd.13348","article-title":"Repigmentation of vitiligo with oral baricitinib","volume":"61","author":"Mumford","year":"2020","journal-title":"Australas. J. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Dong, J., Huang, X., Ma, L.-P., Qi, F., Wang, S.-N., Zhang, Z.-Q., Wei, S.-N., Gao, L., and Liu, F. (2022). Baricitinib is Effective in Treating Progressing Vitiligo in vivo and in vitro. Dose-Response, 20.","DOI":"10.1177\/15593258221105370"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2147\/CCID.S396430","article-title":"Excellent Repigmentation of Generalized Vitiligo with Oral Baricitinib Combined with NB-UVB Phototherapy","volume":"16","author":"Li","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Su, X., Luo, R., Ruan, S., Zhong, Q., Zhuang, Z., Xiao, Z., Zhang, P., Cheng, B., Gong, T., and Ji, C. (2023). Efficacy and tolerability of oral upadacitinib monotherapy in patients with recalcitrant vitiligo. J. Am. Acad. Dermatol.","DOI":"10.1016\/j.jaad.2023.07.1016"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2200873","DOI":"10.1080\/09546634.2023.2200873","article-title":"Concurrent vitiligo and atopic dermatitis successfully treated with upadacitinib: A case report","volume":"34","author":"Pan","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/ajd.13572","article-title":"Two cases of vitiligo vulgaris treated with topical Janus kinase inhibitor delgocitinib","volume":"62","author":"Yagi","year":"2021","journal-title":"Australas. J. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000514198","article-title":"Psoriasis, Vitiligo, and Biologic Therapy: Case Report and Narrative Review","volume":"13","author":"Burlando","year":"2021","journal-title":"Case Rep. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jdcr.2017.07.009","article-title":"Effective use of ustekinumab in a patient with concomitant psoriasis, vitiligo, and alopecia areata","volume":"3","author":"Elkady","year":"2017","journal-title":"JAAD Case Rep."},{"key":"ref_41","first-page":"534","article-title":"Treatment of generalized vitiligo with anti-TNF-\u03b1 Agents","volume":"11","author":"Alghamdi","year":"2012","journal-title":"J. Drugs Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000102044","article-title":"Etanercept in the Treatment of Vitiligo","volume":"215","author":"Rigopoulos","year":"2007","journal-title":"Dermatology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/15569527.2011.560913","article-title":"Tumor necrosis factor-\u03b1? in vitiligo: Direct correlation between tissue levels and clinical parameters","volume":"30","author":"Kim","year":"2011","journal-title":"Cutan. Ocul. Toxicol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2165\/1153424-S0-000000000-00000","article-title":"A Patient with psoriasis and vitiligo treated with etanercept","volume":"11","author":"Campanati","year":"2010","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2165\/1153429-S0-000000000-00000","article-title":"Etanercept in a Patient with Severe Psoriasis and Latent Viral Hepatic Disease and Latent Tuberculosis","volume":"11","author":"Prestinari","year":"2010","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2310\/7750.2011.10068","article-title":"Worsening of vitiligo and onset of new psoriasiform dermatitis following treatment with infliximab","volume":"15","author":"AlGhamdi","year":"2011","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000112932","article-title":"Vitiligo improvement in a patient with ankylosing spondylitis TREATED with Infliximab","volume":"216","year":"2008","journal-title":"Dermatology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/omcr\/omz134","article-title":"Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris","volume":"2020","author":"Palazzo","year":"2020","journal-title":"Oxf. Med. Case Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e15305","DOI":"10.1111\/dth.15305","article-title":"Segmental vitiligo following acitretin treatment for infantile generalized pustular psoriasis resulting in repigmentation under secukinumab therapy","volume":"35","author":"Yang","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/pcmr.12789","article-title":"IL-17A is not a treatment target in progressive vitiligo","volume":"32","author":"Speeckaert","year":"2019","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/cei.12168","article-title":"Treatment of vitiligo with a chimeric monoclonal antibody to CD20: A pilot study","volume":"174","year":"2013","journal-title":"Clin. Exp. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"E446","DOI":"10.1111\/ajd.13346","article-title":"Repigmentation of acrofacial vitiligo with subcutaneous tildrakizumab","volume":"61","author":"Jerjen","year":"2020","journal-title":"Australas. J. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1111\/jdv.19162","article-title":"Topical ruxolitinib: A new treatment for vitiligo","volume":"37","author":"Tavoletti","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1468-3083.2011.04215.x","article-title":"Acral lesions of vitiligo: Why are they resistant to photochemotherapy?","volume":"26","author":"Esmat","year":"2011","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.2147\/JIR.S356316","article-title":"Application of Baricitinib in Dermatology","volume":"15","author":"Zhang","year":"2022","journal-title":"J. Inflamm. Res."},{"key":"ref_56","unstructured":"Padda, I.S., Bhatt, R., and Parmar, M. (2023). StatPearls, StatPearls Publishing."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40265-020-01291-2","article-title":"Delgocitinib: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Custurone, P., Di Bartolomeo, L., Irrera, N., Borgia, F., Altavilla, D., Bitto, A., Pallio, G., Squadrito, F., and Vaccaro, M. (2021). Role of Cytokines in Vitiligo: Pathogenesis and Possible Targets for Old and New Treatments. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111429"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00403-019-01996-9","article-title":"Predominant role of innate pro-inflammatory cytokines in vitiligo disease","volume":"312","author":"Gholijani","year":"2020","journal-title":"Arch. Dermatol. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/jdv.13759","article-title":"New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases","volume":"31","author":"Bagny","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamadermatol.2023.2787","article-title":"Mental Health and Psychosocial Quality-of-Life Burden among Patients with Vitiligo: Findings From the Global VALIANT Study","volume":"159","author":"Bibeau","year":"2023","journal-title":"JAMA Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaad.2009.03.022","article-title":"The burden of vitiligo: Patient characteristics associated with quality of life","volume":"61","author":"Homan","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.det.2016.11.002","article-title":"Quality of Life, Burden of Disease, Co-morbidities, and Systemic Effects in Vitiligo Patients","volume":"35","author":"Elbuluk","year":"2017","journal-title":"Dermatol. Clin."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Hla\u010da, N., \u017dagar, T., Ka\u0161telan, M., Brajac, I., and Prpi\u0107-Massari, L. (2022). Current Concepts of Vitiligo Immunopathogenesis. Biomedicines, 10.","DOI":"10.3390\/biomedicines10071639"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1203475420972340","article-title":"Cutaneous JAK Expression in Vitiligo","volume":"25","author":"Motaleb","year":"2021","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/14740338.2020.1729737","article-title":"Safety of the current drug treatments for vitiligo","volume":"19","author":"Lotti","year":"2020","journal-title":"Expert Opin. Drug Saf."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/23\/7486\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:37:13Z","timestamp":1760132233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/23\/7486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,4]]},"references-count":66,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["jcm12237486"],"URL":"https:\/\/doi.org\/10.3390\/jcm12237486","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,4]]}}}